You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The eight-month contract is for Abbott to provide 50 million BinaxNow SARS-CoV-2 antigen tests with the ordering period ending on Oct. 31.
The center also released updated guidance about how testing can be used as screening intervention, particularly in specific congregate settings.
With $1.2 billion in funding earmarked for more than 40 projects, the portfolio represents a path out of the SARS-CoV-2 pandemic for the US.
The administration will expand COVID-19 testing for schools and underserved populations, increase manufacturing of testing supplies, and increase genomic sequencing.
The collaborators are requesting submissions including budget proposals to scale all supporting components of diagnostic test manufacturing.
The organization also supported the recommendation to include $1.75 billion in funding for the US Centers for Disease Control and Prevention.
The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.
The test, a version of the company's rapid SARS-CoV-2 assay, will be designed for both point-of-care and at-home use as an over-the-counter product.
The test was the first OTC at-home test for the coronavirus to receive EUA from the FDA in December. The US will procure 8.5 million tests.
Under the plan, the president will establish a national pandemic testing board to oversee implementation of a unified approach to testing.